A practical reference on wound model: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-03 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Thorium, protactinium, and uranium, with their dominant oxidation states of +4, +5, and +6 respectively, fooled scientists into thinking they belonged below hafnium, tantalum, and tungsten, rather than below the lanthanide series, which was at the time viewed as a fluke, and whose members all have dominant +3 states; neptunium, on the other hand, has a much rarer, more unstable +7 state, with +4 and +5 being the most stable. Upon finding that plutonium and the other transuranic elements also have dominant +3 and +4 states, along with the discovery of the f-block, the actinide series was firmly established. While the question of whether Fermi's experiment had produced element 93 was stalemated, two additional claims of the discovery of the element appeared, although unlike Fermi, they both claimed to have observed it in nature. The first of these claims was by Czech engineer Odolen Koblic in 1934 when he extracted a small amount of material from the wash water of heated pitchblende. He proposed the name bohemium for the element, but after being analyzed it turned out that the sample was a mixture of tungsten and vanadium. The other claim, in 1938 by Romanian physicist Horia Hulubei and French chemist Yvette Cauchois, claimed to have discovered the new element via spectroscopy in minerals. They named their element sequanium, but the claim was discounted because the prevailing theory at the time was that if it existed at all, element 93 would not exist naturally.
{\displaystyle {\begin{aligned}{\boldsymbol {\omega }}&=\nabla \times \mathbf {u} \\\left(\mathbf {u} \cdot \nabla \right)\mathbf {u} &=\nabla \left({\frac {1}{2}}\mathbf {u} \cdot \mathbf {u} \right)-\mathbf {u} \times {\boldsymbol {\omega }}\\\nabla \times \left(\mathbf {u} \times {\boldsymbol {\omega }}\right)&=-{\boldsymbol {\omega }}\left(\nabla \cdot \mathbf {u} \right)+\left({\boldsymbol {\omega }}\cdot \nabla \right)\mathbf {u} -\left(\mathbf {u} \cdot \nabla \right){\boldsymbol {\omega }}\\[4pt]\nabla \cdot {\boldsymbol {\omega }}&=0\\[4pt]\nabla \times \nabla \phi &=0\end{aligned}}}
On 16 November, Olivey decided that holding the point any longer was pointless and ordered his men to split up, escape by any means possible and re-assemble in Cairo. Over half of the unit reached Egypt.
Sources: en.wikipedia.org
Burrows (1960), author and journalist; founder of the Alliance to Rescue Civilization Thomas Lippman (1961), journalist and author specializing in the Middle East, correspondent for The Washington Post Lars-Erik Nelson (1962), New York Daily News columnist Allen Young (1962), journalist, author, political activist Bernard L. Stein (1963), journalist and winner of the Pulitzer Prize for Editorial Writing in 1998 Michael Drosnin (1966), journalist and author on the Bible code Juan Gonzalez (1969), New York Daily News columnist Jeffrey Bruce Klein (1969), investigative journalist and co-founder of Mother Jones James Simon Kunen (1970), author of articles for Newsday, People, The New York Times Magazine and the novel The Strawberry Statement Glenn Frankel (1971), journalist for The Washington Post, winner of the 1989 Pulitzer Prize for International Reporting Juris Kaža (1971), journalist for Latvian News Agency LETA Jonathan Freedman (1972), journalist and winner of the 1987 Pulitzer Prize for Editorial Writing John Brecher (1973), journalist and wine critic for The Wall Street Journal Michael Wolff (1975), media columnist for New York Magazine and Vanity Fair, author of controversial book Fire and Fury on Donald Trump Bill Minutaglio (1976), journalist, biographer of George W. Bush D. D.
The Blue Book, formally titled Nomenclature of Organic Chemistry, is a collection of recommendations on organic chemical nomenclature. Updates are published at irregular intervals. A full edition was published in 1979, an abridged and updated version of which was published in 1993 as A Guide to IUPAC Nomenclature of Organic Compounds. Both of these are now out-of-print in their paper versions, but are available free of charge in electronic versions. After the release of a draft version for public comment in 2004 and the publication of several revised sections in the journal Pure and Applied Chemistry, a fully revised version was published in print in 2013.
Post-translational modifications can incorporate more complex, large molecules into the folded protein structure. One common example of this is glycosylation, the addition of a polysaccharide molecule, which is widely considered to be most common post-translational modification. In glycosylation, a polysaccharide molecule (known as a glycan) is covalently added to the target protein by glycosyltransferases enzymes and modified by glycosidases in the endoplasmic reticulum and Golgi apparatus. Glycosylation can have a critical role in determining the final, folded 3D structure of the target protein. In some cases glycosylation is necessary for correct folding. N-linked glycosylation promotes protein folding by increasing solubility and mediates the protein binding to protein chaperones. Chaperones are proteins responsible for folding and maintaining the structure of other proteins. There are broadly two types of glycosylation, N-linked glycosylation and O-linked glycosylation. N-linked glycosylation starts in the endoplasmic reticulum with the addition of a precursor glycan. The precursor glycan is modified in the Golgi apparatus to produce complex glycan bound covalently to the nitrogen in an asparagine amino acid. In contrast, O-linked glycosylation is the sequential covalent addition of individual sugars onto the oxygen in the amino acids serine and threonine within the mature protein structure.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.